Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

  • Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer
  • Innate to receive $5M milestone payment from AstraZeneca

https://finance.yahoo.com/news/innate-pharma-announces-iph5201-phase-050000097.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.